Silexion Therapeutics Corp (SLXN:NASDAQ) closed at $0.189 on October 23, 2026, up 14.29% on the day. The stock trades 99.5% below its 52-week high of $35.60 and 33.0% above its 52-week low of $0.142. Over the past year, it lost 94.5%. Silexion Therapeutics Corp is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, SLXN closed higher on 91 days (36%). Its best day was December 1, 2025 (+875.27%) and its worst was August 12, 2026 (-56.14%). The stock moved 10% or more in a single session 45 times. It opened at least 5% above the previous day's high 4 times.
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Find more stocks like SLXN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.